What is PT-141?

Q: What is PT-141? A:Bremelanotide (tentative brand name Rekynda; former developmental code name PT-141) is a peptide melanocortin receptor agonist which is under development by Palatin Technologies as a treatment for female sexual dysfunction. It works equally effectively on both male and female humans.

When will pt 141 be available?

Being that PT 141 is in research and development stage means that the pharmaceutical company Palatin is still working with the FDA to legally sell it with a doctors prescription. From what it looks like PT 141 is set to be available from a doctor or approved as a new drug in 2019.

How does pt 141 work in hemorrhagic shock?

In 2009, PT-141 was modified slightly and investigated as a potential treatment for hemorrhagic shock. Because PT-141 binds to both MC-1R and MC-4R, it reduces ischemia and protects tissues against inadequate blood supply in the setting of hypovolemic (hemorrhagic) shock.

What is pt 141 (bremelanotide)?

This article will cover everything you wanted to know about the research peptide PT 141, which is also known as Bremelanotide. Technically speaking PT 141 is a drug that is being developed by the pharmaceutical company Palatin Technologies.